Sotagliflozin fda approval

Sotagliflozin (Inpefa) for Heart Failure The FDA has approved sotagliflozin (Inpefa – Lexicon), an oral sodium-glucose cotransporter 1 and 2 (SGLT1/2)

- Lexicon Pharmaceuticals announced the FDA approval of Inpefa (sotagliflozin), to reduce the risk of cardiovascular (CV) death

The FDA has approved Lexicon Pharmaceuticals 39; Inpefa (sotagliflozin) to cut the risk of cardiovascular death and hospitalization for

Sotagliflozin got FDA approval for the treatment of heart failure. On 26th May 2024, the FDA approved Inpefa tablets for treating patients with heart failure. Originally, Sotagliflozin was approved in 2024 by the EMA (European Medical Agency) for treating patients with Type 1 Diabetes under the brand name Zynquista.

Soon to hit the market is a new heart failure drug sotagliflozin (brand name Inpefa), which was approved by the FDA on . A

by A Gass 2024In the United States, dapagliflozin, empagliflozin, and sotagliflozin are approved FDA approves treatment for wider range of patients with heart failure.

FDA on whether to recommend sotagliflozin for approval (FDA) on whether to recommend diabetes drug Zynquista (sotagliflozin) for approval.

The FDA approval of sotagliflozin (Inpefa) for the treatment of heart failure was announced by Lexicon Pharmaceuticals on .

In the United States, dapagliflozin, empagliflozin, and sotagliflozin are approved FDA approves treatment for wider range of patients with heart failure.